Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.41 HKD
360.23 M HKD
1.27 B HKD
593.69 M
About DAWNRAYS PHARMACEUTICAL HLDGS
Sector
CEO
Li Wei Yu
Headquarters
Hong Kong
Website
Founded
1995
FIGI
BBG000FMB261
Dawnrays Pharmaceutical Holdings Ltd. operates as an investment holding company, which engages in the development, manufacturing and selling of cephalosporin antibiotics, and various system specific medicines. It operates through the following business segments: Intermediates & Bulk Medicines, and Finished Drugs. The Intermediates & Bulk Medicines segment engages in the manufacturing and selling of intermediates and bulk medicines. The Finished Drugs segment engages in the manufacturing and selling of antibiotics finished drugs and non-antibiotics finished drugs. The company was founded on December 8, 1995 and is headquartered in Hong Kong.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 2348 is 1.23 HKD — it hasn't changed in the past 24 hours. Watch DAWNRAYS PHARMACEUTICAL HLDGS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange DAWNRAYS PHARMACEUTICAL HLDGS stocks are traded under the ticker 2348.
2348 stock hasn't changed in a week, the month change is a −1.60% fall, over the last year DAWNRAYS PHARMACEUTICAL HLDGS has showed a 14.95% increase.
2348 reached its all-time high on Oct 22, 2014 with the price of 4.07 HKD, and its all-time low was 0.22 HKD and was reached on Jun 15, 2005. View more price dynamics on 2348 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
2348 stock is 1.63% volatile and has beta coefficient of 0.30. Track DAWNRAYS PHARMACEUTICAL HLDGS stock price on the chart and check out the list of the most volatile stocks — is DAWNRAYS PHARMACEUTICAL HLDGS there?
Today DAWNRAYS PHARMACEUTICAL HLDGS has the market capitalization of 1.85 B, it has decreased by −1.60% over the last week.
Yes, you can track DAWNRAYS PHARMACEUTICAL HLDGS financials in yearly and quarterly reports right on TradingView.
DAWNRAYS PHARMACEUTICAL HLDGS is going to release the next earnings report on Mar 21, 2025. Keep track of upcoming events with our Earnings Calendar.
2348 net income for the last half-year is 534.28 M HKD, while the previous report showed 75.69 M HKD of net income which accounts for 605.90% change. Track more DAWNRAYS PHARMACEUTICAL HLDGS financial stats to get the full picture.
DAWNRAYS PHARMACEUTICAL HLDGS dividend yield was 7.62% in 2023, and payout ratio reached 33.31%. The year before the numbers were 6.62% and 31.67% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 21, 2024, the company has 1.14 K employees. See our rating of the largest employees — is DAWNRAYS PHARMACEUTICAL HLDGS on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. DAWNRAYS PHARMACEUTICAL HLDGS EBITDA is 340.92 M HKD, and current EBITDA margin is 31.35%. See more stats in DAWNRAYS PHARMACEUTICAL HLDGS financial statements.
Like other stocks, 2348 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DAWNRAYS PHARMACEUTICAL HLDGS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So DAWNRAYS PHARMACEUTICAL HLDGS technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating DAWNRAYS PHARMACEUTICAL HLDGS stock shows the neutral signal. See more of DAWNRAYS PHARMACEUTICAL HLDGS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.